sure, there's more where the other cheap options came from, they just keep granting them. Poor Spector is so underpaid, he could never make it on that $686k salary, probably needs a moat for his San Diego castle. Those options had a lot of time remaining. The insider selling is getting old. Heading to $5 tomorrow it appears. Sad they are helping the shorts out.
wondering if DJ is in hiding and fed Charlie to the wolves, but hoping he's on his way out. Let's see who presents next. Charlie is obviously inexperienced at presenting on business issues, needs more practice. Hope he listens to the cc replay learns and prepares more if there is a next time.
Charlie needs to slow down and speak more clearly.
The best comment I heard from the call came from the analyst who asked...why would you use anything other than the proven linker and Dm1, so basically why not become a factory, take antibody, add the same linker and killing agent proven to work in Kadcyla and crank out successful new products. I believe CH and a few other smart posters have made a similar argument. Don't get cute, don't over think, do what works.
The most stupid comment was that they would announce a decision on 901 next week, so apparently they intend to talk more about the failure. Here's an idea STHU about 901, let it die a silent death, move on, start applying the proven technology to enhance other antibodies through partners, it's a no brainer!!!
Let John and his team focus on the new technology and do new licensing deals for every active antibody using proven Kadcyla technology and let the partner do the development work since you can't develop.
Finally, the BT drug looks interesting. Buy in at the low cost and license your rights out to the highest bidder for a profit. Another no-brainer. This business should be printing cash if run properly. Instead we have a bunch of brain-dead, self serving dopes in control. I feel bad for John Lambert and co, he's the only one adding value then the dopes in charge screw things up.
unfortunately, these are not buys, they are the BOD stealing cheap, free shares for doing NOTHING. We should report this suspicous timing to the SEC, I am getting tired ot their terrible corp. governance!
Feel free to add your comments about the AF SRPT debacle call by AF on FierceBiotech. That clown deserves to rot in jail for his crimes against biotech investors IMO + a sprinkle of half truths to avoid saying anything for which I can be prosecuted of course.
Not sure about that, but SRPT blow up might have got management's attention. FDA approval and drug launch is risky business for a small biopharma. If they can get a good offer in the $30's now, they should consider it. IMO, long and hopeful, but experienced enough in biotech to know risk is not low.
The CEO has zero communication skills. They once employed a senior level, strategic thinking IR pro David Wallsey and apparently downsized him at some point and kept the manager, professional ball girl instead. Now she's the VP of IR. She's a nice and attractive young lady, she's learning and growing, but not at the level of David, or other industry execs. Maybe Jack does not want a strong IR pro and prefers someone more junior that will not stand up to him. He prefers a weak CFO. Just a theory.
amen, Dan is a failure and he failed to communicate. Shareholders deserve better, he must go!
it bruised both my wallet and my ego, I don;t carry a pocketbook, or a man bag. Looks like another good dip to buy here IMO.
not even close, maybe 10MM at the very most and that's after expiration assuming price is above $5. If price is below $5 it's more like 5MM. All a guess.
I am more interested to know if Person of Interest will really really kill off Fusco tonight and if the Toledo Rockets can beat Buffalo. I am holding ARNA until at least $8, so this is all noise.
Keep an eye on IMGN, it's a LT winner, potential acquisition target beaten down by an expected failure (their old technology) that was piled on to by AF and the other short criminals. It's a buy on dips IMO.
If anyone who posts here attends the meeting, please post a summary. If not, I think a friend of an IV poster is planning to attend, maybe we get something from them.
News must be released when it happens, they don't control the timing of news. DJ had nothing to do with the technology, what he is supposed to do is put the right team together to make the most of it. The team that evaluates a drug's potential failed in the case of 901. They wasted millions, capital and time that would have been better spent speeding up the new molecules. I am not saying he has an easy job, I think they need a CEO that has successfully developed a drug. Dan has not shown that he's the best person to lead IMGN forward, develop drugs, make the best decisions for shareholders, he's been opportunistic in granting himself and his team options at a low price than selling them. If he is building shareholder value, I have no problems with a CEO making big $, but IMGN has been a public company for 2+ years and might have gone from $12 on the IPO to $15 in 20 years. That's not CELG, REGN, PCYC, ONXX. Let's find someone that been a leader with a successful, high-growth biotech that took drugs from early development through FDA approval, or turned around and sold a company. Tony Coles, Howard Pien from the BOD come to mind and Doug Williams who sold ZGEN and is now at Biogen might be good.
Jack should retire and maintain a seat on the BOD, or run the research, but not be the President or CEO IMO.
AKA the bagel and BS meeting. If Dan's lips are moving...If Dan is MIA, then we will have a news story. I would like to know which BOD members are attending Dan's BS session. Someone try to make Carol smile, she always seems so unhappy.
Are you people not smart enough to ignore this fraud. Oh no, AF is going to write an article. Someone should tell the other TSC writer who called it a buy today.